Scarica l'app Stockscreener
18.26
2.47%
0.44
Dopo l'orario di chiusura:
18.27
0.010
+0.05%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché APLS Giù?
Forum
Previsione
Apellis Pharmaceuticals Inc Borsa (APLS) Ultime notizie
Apellis Pharma general counsel Watson sells $93k in stock By Investing.com - Investing.com Canada
Comprehensive Age-related Macular Degeneration Market Analysis: Trends and Developments Across All Types - GlobeNewswire Inc.
How To Trade (APLS) - news.stocktradersdaily.com
Fierce Biotech Layoff Tracker 2025: ADC Tx lets go of 30% of workers; Vertex sheds 125 staffers - Fierce Biotech
Apellis at Goldman Sachs Conference: Strategic Insights on Product Growth - Investing.com
Apellis at Goldman Sachs Conference: Strategic Insights on Product Growth By Investing.com - Investing.com Nigeria
Transcript : Apellis Pharmaceuticals, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-11-2025 10 - MarketScreener
Apellis phase 3 Empaveli data demonstrates sustained proteinuria reduction - MSN
Sobi and Apellis report new data from Phase III trial for C3G and IC-MPGN - Yahoo
Wealth Enhancement Advisory Services LLC Has $1.07 Million Stock Holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - Defense World
SHAREHOLDER ALERT: Potential Recovery for Apellis Pharmaceuticals, Inc. (APLS) Investors Affected by Stock Drop – Levi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
Apellis, Sobi present data from open-label period of Phase 3 VALIANT study - Yahoo Finance
Apellis Pharmaceuticals (APLS) Reports Promising Phase 3 Study R - GuruFocus
Apellis and Sobi Announce EMPAVELI® (pegcetacoplan) Showed Susta - GuruFocus
Apellis Pharmaceuticals (APLS) Reports Promising Empaveli Data - GuruFocus
Why Is Apellis Pharmaceuticals (APLS) Up 7.2% Since Last Earnings Report? - Yahoo Finance
Sobi and Apellis data underscore Aspaveli potential - The Pharma Letter
Apellis Pharmaceuticals, Inc. and Sobi Announce EMPAVELI®? (Pegcetacoplan) Showed Sustained Efficacy at One Year in Phase 3 Study for C3G and Primary IC-MPGN - MarketScreener
Apellis Pharmaceuticals, Sobi Report Empaveli's Sustained Efficacy at 1 Year in Phase 3 Study - MarketScreener
Apellis and Sobi Announce EMPAVELI® (pegcetacoplan) Showed Sustained Efficacy at One Year in Phase 3 Study for C3G and Primary IC-MPGN - The Manila Times
Apellis Pharmaceuticals and Sobi Present Promising Phase 3 VALIANT Study Results for EMPAVELI in Treating Rare Kidney Diseases at European Renal Association Congress - Nasdaq
Apellis and Sobi Announce EMPAVELI® (pegcetacoplan) Showed - GlobeNewswire
Breakthrough: EMPAVELI Achieves 68% Disease Reduction in Rare Kidney Conditions as FDA Decision Approaches - Stock Titan
High Growth Tech Stocks To Watch In The US June 2025 - Yahoo Finance
Apellis Pharmaceuticals Holds Annual Stockholders Meeting - TipRanks
Apellis Pharmaceuticals to Present at the Goldman Sachs 46th Ann - GuruFocus
Apellis Pharmaceuticals to Present at the Goldman Sachs 46th Annual Global Healthcare Conference | APLS Stock News - GuruFocus
Apellis Pharmaceuticals to Present at the Goldman Sachs 46th Annual Global Healthcare Conference - The Manila Times
Apellis Reveals New Insights at Goldman Sachs Healthcare Conference: How to Watch Live - Stock Titan
Why Apellis Pharmaceuticals, Inc. (APLS) Skyrocketed On Monday - Yahoo Finance
Wells Fargo & Company Issues Positive Forecast for Apellis Pharmaceuticals (NASDAQ:APLS) Stock Price - Defense World
Apellis Pharmaceuticals (NASDAQ:APLS) Shares Up 7.7% Following Analyst Upgrade - Defense World
These 10 Stocks Blew Past Expectations - Insider Monkey
Apellis Pharmaceuticals (APLS) Receives Price Target Boost from Wells Fargo | APLS Stock News - GuruFocus
Wells Fargo Adjusts Price Target for Apellis (APLS) to $29 | APLS Stock News - GuruFocus
Wells Fargo raises Apellis Pharmaceuticals stock price target to $29 By Investing.com - Investing.com Canada
Wells Fargo Adjusts Price Target on Apellis (APLS) Amid Product Launch Anticipation | APLS Stock News - GuruFocus
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Purchases 1,578 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - Defense World
Apellis Pharmaceuticals Insiders Sell US$3.1m Of Stock, Possibly Signalling Caution - simplywall.st
(APLS) Long Term Investment Analysis - news.stocktradersdaily.com
Equities Analysts Offer Predictions for APLS Q2 Earnings - Defense World
Nuveen Asset Management LLC Has $15.67 Million Stock Position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - Defense World
Citigroup Has Lowered Expectations for Apellis Pharmaceuticals (NASDAQ:APLS) Stock Price - Defense World
Expert Outlook: Apellis Pharmaceuticals Through The Eyes Of 17 Analysts - Benzinga
APLS: Citigroup Lowers Price Target for Apellis Pharmaceuticals | APLS Stock News - GuruFocus
Apellis (APLS) Target Price Reduced by Citi Amidst Adjusted Grow - GuruFocus
Apellis (APLS) Target Price Reduced by Citi Amidst Adjusted Growth Outlook | APLS Stock News - GuruFocus
How the (APLS) price action is used to our Advantage - news.stocktradersdaily.com
Apellis Pharmaceuticals Stock: Have Some Patience (NASDAQ:APLS) - Seeking Alpha
Captrust Financial Advisors Buys Shares of 12,629 Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - Defense World
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Given Consensus Rating of “Moderate Buy” by Analysts - Defense World
Mizuho Cuts Apellis Pharmaceuticals (NASDAQ:APLS) Price Target to $20.00 - Defense World
Northern Trust Corp Has $17.46 Million Stake in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - Defense World
0.68%
0.50%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):